Retinal detachment occurs when fluid separates the retina (a thin, light sensing tissue) from its usual attachment at the back of the eye. If detached, these retinal cells lose their normal blood supply and begin to die, which is the primary cause of vision loss in retinal detachment. The 'macula' refers to the very centre of the retina, with the highest density of retinal cells, most responsible for vision. Significant vision loss occurs when this part of the retina becomes separated (termed a 'macula-off retinal detachment'). Typically, surgery is required to repair the retinal detachment.
Supporting the health of retinal cells at the macula may prolong their survival after detachment and their recovery postoperatively. Recent evidence has shown that boosting our nicotinamide adenine dinucleotide (NAD+) levels may improve the health of these cells and prolong their survival if detached. Oral Nicotinamide Riboside (NR) is converted into NAD+, and while not studied for macula-off retinal detachments, has been safely used in a range of other conditions. This study is designed to help evaluate the safety and tolerability of NR to help preserve vision in people diagnosed with macula-off retinal detachment.
This study drug is given as an oral supplement (tablet) at the time of retinal detachment diagnosis, and daily for 20 weeks thereafter. The drug aims to prolong survival of cells in the retina (and macula) and their recovery after surgery.
The long-term goal of this treatment is to reduce loss of vision after retinal detachment. The researchers will compare NR to a placebo (a look-alike substance that contains no drug) to see if NR has a positive effect on photoreceptor survival and quality of vision postoperatively.
NR has been approved by the Therapeutic Goods Administration in Australia for many purposes but has not been approved for use in retinal detachment treatment.

开始日期2025-05-01

申办/合作机构-

NCT06567717

/ Not yet recruiting临床2期IIT

Feasibility of a Decentralized Double-Blind Randomized Controlled Trial of Zinc and Nicotinamide Riboside for the Treatment of Idiopathic Pulmonary Fibrosis

The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can treat iIPF. The main questions are:
Can the investigators recruit participants, and can participants complete study procedures without physically coming into specific clinical trial sites? Can people with IPF experience improvement in symptoms, quality of life, or functioning if they are take these supplements? The investigators will compare zinc and nicotinamide riboside to matched placebos (look-alike substances that contain no drug) to see if these supplements treat symptoms or lung function in people with IPF.
Participants will:
Take drug these supplements twice a day for 24 weeks. Complete pulmonary function testing and six minute walk tests with their own pulmonologists every 12 weeks. Complete a high resolution CT scan at the start and end of the study. Complete video study visits with the research team every 4 weeks. Complete surveys about their symptoms and the number of times they take the medication.

开始日期2025-01-01

申办/合作机构

Cedars-Sinai Health System

NCT04614714

/ Not yet recruiting临床2/3期IIT

Nicotinamide Riboside and Milk Production in the NICU

Breastfeeding has well-established immunity and developmental benefits for newborns, yet mothers of preterm infants often struggle to provide sufficient breast milk. The investigators hypothesize that supplementing mothers of preterm infants with nicotinamide riboside (NR) during early postpartum will result in increased milk production. NR is a unique precursor to NAD+, which functions in whole-body metabolism, including that which supports the elevated energy demands of lactation. In lactating rats, NR supplementation improved milk quantity and quality, with metabolic benefits for the mother and lasting protective advantages for the offspring. No studies have been conducted to date that explore the short- or long-term use of NR for increasing milk supply in lactating women. This study will follow a small cohort of women and very preterm infants in the NICU throughout two intervention phases-- one in which each mother will randomly receive either NR or a placebo, then the opposite treatment-- to determine the effect of maternal NR supplementation on expressed milk volume and other markers of metabolism.

开始日期2024-12-01

申办/合作机构

University of California, Davis

100 项与烟酰胺核糖相关的临床结果

登录后查看更多信息

100 项与烟酰胺核糖相关的转化医学

登录后查看更多信息

100 项与烟酰胺核糖相关的专利（医药）

登录后查看更多信息

1,124

项与烟酰胺核糖相关的文献（医药）

2025-04-01·ESC Heart Failure

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

Review

作者: Song, Jia ; Zhang, Wei ; Liu, Xiaohong ; Yao, Shun ; Li, Shujuan ; Fang, Zhuyubing ; Raza, Umar ; Lu, Junyan

Abstract:

Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac amyloidosis, elevating susceptibility to chronic heart failure (HF) in the elderly. Age‐related cardiac dysfunction stems from prolonged exposure to genomic, epigenetic, oxidative, autophagic, inflammatory and regenerative stresses, along with the accumulation of senescent cells. Concurrently, age‐related structural and functional changes in the vascular system, attributed to endothelial dysfunction, arterial stiffness, impaired angiogenesis, oxidative stress and inflammation, impose additional strain on the heart. Dysregulated mechanosignalling and impaired nitric oxide signalling play critical roles in the age‐related vascular dysfunction associated with HF. Metabolic aging drives intricate shifts in glucose and lipid metabolism, leading to insulin resistance, mitochondrial dysfunction and lipid accumulation within cardiomyocytes. These alterations contribute to cardiac hypertrophy, fibrosis and impaired contractility, ultimately propelling HF. Systemic low‐grade chronic inflammation, in conjunction with the senescence‐associated secretory phenotype, aggravates cardiac dysfunction with age by promoting immune cell infiltration into the myocardium, fostering HF. This is further exacerbated by age‐related comorbidities like coronary artery disease (CAD), atherosclerosis, hypertension, obesity, diabetes and chronic kidney disease (CKD). CAD and atherosclerosis induce myocardial ischaemia and adverse remodelling, while hypertension contributes to cardiac hypertrophy and fibrosis. Obesity‐associated insulin resistance, inflammation and dyslipidaemia create a profibrotic cardiac environment, whereas diabetes‐related metabolic disturbances further impair cardiac function. CKD‐related fluid overload, electrolyte imbalances and uraemic toxins exacerbate HF through systemic inflammation and neurohormonal renin‐angiotensin‐aldosterone system (RAAS) activation. Recognizing aging as a modifiable process has opened avenues to target systemic aging in HF through both lifestyle interventions and therapeutics. Exercise, known for its antioxidant effects, can partly reverse pathological cardiac remodelling in the elderly by countering processes linked to age‐related chronic HF, such as mitochondrial dysfunction, inflammation, senescence and declining cardiomyocyte regeneration. Dietary interventions such as plant‐based and ketogenic diets, caloric restriction and macronutrient supplementation are instrumental in maintaining energy balance, reducing adiposity and addressing micronutrient and macronutrient imbalances associated with age‐related HF. Therapeutic advancements targeting systemic aging in HF are underway. Key approaches include senomorphics and senolytics to limit senescence, antioxidants targeting mitochondrial stress, anti‐inflammatory drugs like interleukin (IL)‐1β inhibitors, metabolic rejuvenators such as nicotinamide riboside, resveratrol and sirtuin (SIRT) activators and autophagy enhancers like metformin and sodium‐glucose cotransporter 2 (SGLT2) inhibitors, all of which offer potential for preserving cardiac function and alleviating the age‐related HF burden.

2025-04-01·BONE

The protection of nicotinamide riboside against diabetes mellitus-induced bone loss via OXPHOS

Article

作者: Dai, Shiyou ; Meng, Xiangyuan ; Yang, Xingxiang ; Gao, Tianlin ; Gong, Jianbao ; Zhang, Junwei ; Tian, Chunyan ; Xie, Chenqi ; Gao, Jie

Diabetes mellitus is a global disease that results in various complications, including diabetic osteoporosis. Prior studies have indicated a correlation between low levels of nicotinamide adenine dinucleotide (NAD⁺) and diabetes-related complications. Nicotinamide riboside (NR), a widely utilized precursor vitamin of NAD⁺, has been demonstrated to enhance age-related osteoporosis through the Sirt1/FOXO/β-catenin pathway in osteoblast progenitors. However, the impact of NR on bone health in diabetes mellitus remains unclear. In this study, we assessed the potential effects of NR on bone in diabetic mice. NR was administered to high-fat diet (HFD)/streptozotocin (STZ)-induced type 2 diabetic mice (T2DM), and various parameters, including metabolic indicators, bone quality, bone metabolic markers, and RNA sequences, were measured. Our findings confirmed that HFD/STZ-induced T2DM impaired bone microstructures, resulting in bone loss. NR effectively ameliorated insulin resistance, improved bone microarchitecture, and bone quality, reduced bone resorption, enhanced the Forkhead box O (FOXO) signaling pathway, mitigated the nuclear factor kappa B (NF-kB) signaling pathway, and ameliorated the disorder of the oxidative phosphorylation process (OXPHOS) in diabetic mice. In conclusion, NR demonstrated the capacity to alleviate T2DM-induced bone loss through the modulation of OXPHOS in type 2 diabetic mice. Our results underscore the potential of NR as a therapeutic target for addressing T2DM-related bone metabolism and associated diseases. Further cell-based studies under diabetic conditions, such as in vitro cultures of key cell types (e.g., osteoblasts and osteoclasts), are necessary to validate these findings.

2025-03-04·Journal of the American Heart Association

Nicotinamide Riboside: A Promising Treatment for Type 1 Cardiorenal Syndrome in Myocardial Infarction‐Induced Acute Kidney Injury by Upregulating Nicotinamide Phosphoribosyltransferase‐Mediated Nicotinamide Dinucleotide Levels

Article

作者: Habeichi, Nada J. ; Momken, Iman ; Mericskay, Mathias ; Amin, Ghadir ; Zouein, Fouad A. ; Ghali, Rana ; Diab, Reine ; Booz, George W. ; Tannous, Cynthia ; Boitard, Solene

Background:

Cardiorenal syndrome type 1 is characterized by the development of acute kidney injury following acute cardiac illness and notably acute myocardial infarction (MI). Acute kidney injury is considered an independent risk factor that increases mortality rate substantially. Nicotinamide adenine dinucleotide (NAD) is an important coenzyme in energy metabolism and oxidative phosphorylation, and in its oxidized form it is a substrate for multiple NAD + ‐dependent enzymes such as sirtuins and poly‐ADP ribose polymerases. Decreased cardiac NAD levels, along with a downregulation of NAMPT (nicotinamide phosphoribosyl transferase), have been reported following MI. A compensatory upregulation in NMRK (nicotinamide riboside kinase) 2, an NAD + biosynthetic enzyme that uses nicotinamide riboside (NR) to generate NAD + , takes place in the heart after MI, but the impact on kidney NAD metabolism and function has not been addressed before.

Methods and Results:

MI was induced by ligating the left anterior descending coronary artery in 2‐month‐old C57BL6/J mice, followed by the administration of NR (IP injection, 400 mg/kg per day) for 4 and 7 days. We hypothesized that NR treatment could be a potentially promising therapy for MI‐induced acute kidney injury. Our findings showed no significant improvement in cardiac ejection fraction following NR treatment at days 4 and 7 post‐MI, whereas kidney functions were enhanced and morphological alterations and cell death decreased. The observed renal protection seems to be mediated by an upregulation of NAMPT‐mediated increase in renal NAD levels, notably in the distal tubules.

Conclusions:

Our findings indicate that NR could potentially be a promising therapy for acute kidney injury following an early stage of MI.

项与烟酰胺核糖相关的新闻（医药）

2025-02-04

·PRNewswire

NexGen Health Introduces Niagen Plus IV Therapy: Revolutionizing Cellular Health and Anti-Aging in Silicon Valley

NexGen Health in San Jose introduces Niagen Plus IV Therapy, an advanced treatment that boosts cellular health, enhances energy, and combats aging by replenishing NAD+ levels using nicotinamide riboside (NR). This innovative therapy complements NexGen Health's regenerative medicine offerings, setting a new standard for wellness in Silicon Valley. SAN JOSE, Calif., Feb. 4, 2025 /PRNewswire/ -- NexGen Health, Silicon Valley's premier destination for cutting-edge regenerative wellness, is proud to announce the launch of Niagen Plus IV Therapy, an innovative treatment designed to enhance cellular health, boost energy, and combat the effects of aging. This groundbreaking therapy harnesses the power of nicotinamide riboside (NR), a key precursor to NAD+ (Nicotinamide Adenine Dinucleotide), combined with IV delivery for optimal absorption and faster results. The Science Behind Niagen Plus IV Therapy Continue Reading NexGen Health NAD+ is a vital coenzyme found in all living cells, responsible for energy production, DNA repair, and cellular regeneration. As people age, NAD+ levels naturally decline, leading to fatigue, cognitive decline, and other age-related conditions. Niagen Plus IV Therapy replenishes NAD+ levels by delivering nicotinamide riboside (NR) directly into the bloodstream, bypassing the digestive system to ensure maximum efficacy and rapid cellular uptake. "Our Niagen Plus IV Therapy is a game-changer for patients seeking to improve energy levels, optimize cognitive function, and support overall longevity," said Ilbra Petros, Director of NexGen Health." This treatment is perfect for anyone looking to combat the cellular effects of aging and enhance their vitality." Key Benefits of Niagen Plus IV Therapy Cellular Regeneration: Restores NAD+ levels to support healthier, more resilient cells. Enhanced Energy: Improves mitochondrial function to combat fatigue and sustain energy throughout the day. Cognitive Performance: Boosts brain health, improving focus, memory, and overall mental clarity. Anti-Aging Effects: Supports DNA repair, reduces oxidative stress, and promotes healthy aging. Synergistic Wellness: Complements other treatments offered at NexGen Health, such as NAD therapy, peptides, and IV nutrient infusions. A New Standard of Care in Silicon Valley Located in the heart of San Jose, NexGen Health is renowned for its personalized, concierge-level wellness services. With the addition of Niagen Plus IV Therapy, NexGen Health continues to lead the way in advanced regenerative medicine, offering residents of Silicon Valley and beyond an opportunity to optimize their health at the cellular level. "Niagen Plus IV Therapy represents the future of anti-aging and wellness," added Ilbra. "We are thrilled to bring this innovative treatment to the Bay Area, providing our patients with a scientifically-backed solution to improve their quality of life and unlock their full potential." About NexGen Health NexGen Health is a state-of-the-art wellness center located in San Jose, CA, specializing in advanced regenerative medicine and innovative health solutions. From NAD therapy and peptide treatments to IV nutrient infusions and comprehensive wellness consultations, NexGen Health offers cutting-edge services tailored to individual patient needs. As a leader in cellular health and anti-aging therapies, NexGen Health combines the latest advancements in medical science with concierge-level care to deliver exceptional results. Schedule Your Niagen Plus IV Therapy Consultation Today To learn more about Niagen Plus IV Therapy or schedule a consultation, visit NexGen Health online at or call (408) 400-2967. Media Contact: Ilbra Petros NexGen Health 408-400-2967 [email protected] SOURCE NexGen Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-01-22

·梅斯医学

维生素片“翻车”了？多项研究：或导致癌症风险增加27%，脑转移风险多3.8倍，且无法降低死亡风险和心血管疾病发病率

随着健康养生热潮的兴起，维生素俨然成了“万能小金砖”。更厉害的是，市面上还冒出了一大票“多合一”的复合维生素，打着“全方位呵护健康”的口号，把维生素B、维生素C、维生素D等一股脑装进小小的补充剂里，仿佛吃一颗就能横扫所有健康难题。这些五花八门的补充剂，看起来简直比超人还全能！但问题来了：它们真的有这么神奇，还是我们被“补充剂万能论”给绕晕了头？今天，我们就来扒一扒这些维生素补充剂背后的“翻车”现场！维生素B3补充不当或过度或导致癌症发生率和脑转移风险增加首先，是维生素B3的“翻车”。来自瑞士联邦理工学院的国际研究团队曾经发表的一项研究[1]发现，维生素B3在人体内的一种存在形式——烟酰胺核苷（NR），如果补充不当或过度，反而会增加罹患严重疾病的风险，包括癌症的发生及转移。总的来说，这项研究提示，补充NR会导致癌症的发病率显著升高，明显增加了癌症向大脑转移的可能性。研究人员推测，NR的过度补充会助长癌细胞的转移潜力，降低血脑屏障的完整性，从而增强了癌细胞入侵大脑的能力。晚年阶段减少叶酸摄入，改善代谢，利于长寿说完了维生素B3，再来看看另一种常见的维生素——维生素B9的“翻车事件”。维生素B9（又称叶酸）是一种水溶性维生素，在维持生命基本功能中扮演着不可或缺的角色。那叶酸补充是不是多多益善呢？近期，Life Science Alliance发表的一项研究[2]提出了极具颠覆性的观点：减少老年小鼠的叶酸摄入，能有效改善代谢，帮助延长健康寿命。所以，为什么减少叶酸摄入可能在晚年成为健康寿命的加分项？研究人员也提出了背后潜在的机制。首先，得从“对抗性多效性理论”说起。这个理论听起来有点拗口，但核心很简单：某些在年轻时对健康有益的特性，到了晚年可能变成“拖后腿”的因素。比如，叶酸代谢和雷帕霉素靶点（TOR）途径，年轻时帮助细胞快速生长和修复，但到了老年，细胞生长过快可能会增加一系列健康风险。这种“角色反转”恰好解释了为什么减少叶酸摄入能在晚年带来一定的健康寿命益处。另一个引人关注的机制是IGF-1（胰岛素样生长因子-1）途径。早期研究显示，降低IGF-1活性与延长寿命密切相关。在这项研究中，研究人员也观察到雌性小鼠的IGF-1水平因叶酸摄入减少而降低，这与健康长寿的趋势一致。换句话说，减少叶酸摄入似乎让小鼠“踩了刹车”，避免IGF-1过度活跃带来的负面影响。总的来说，这项研究提示，叶酸补充可能并非“全生命周期通用良策”，老年阶段的低叶酸摄入可能为健康寿命和代谢调节带来有益的影响。不过仍需指出的是，这项研究样本量较小，且仅使用了一种近交系小鼠，因此未来还需进一步探索叶酸摄入减少对人类的影响。维生素D补充剂降低冠心病、中风和全因死亡风险“翻车” 最后再看看另一种颇为常见的维生素——维生素D。提到这种维生素，许多人第一反应就是晒太阳。没错，维生素D又被称为“阳光维生素”。当阳光照射到皮肤，或者我们通过饮食和补充剂摄入维生D时，这种形式的维生素D会先在肝脏转化为25[OH]D。接着，它在肾脏进一步转化为活性形式，开始调节身体的多项功能，比如促进钙的吸收，保护骨骼健康。所以，多“补”点维生素D补充剂对健康是利多还是弊多呢？为了进一步探讨维生素D补充剂与健康结局之间是否存在潜在的因果关系，研究人员进行了孟德尔随机化分析。总的来说，这项研究提示，在较低浓度时，25[OH]D浓度与CHD、中风和全因死亡率呈负相关关系，但这种关联在较高浓度时几乎消失。而且遗传预测25[OH]D浓度总体与这些疾病或全因死亡率之间不存在因果关系。看来，各种维生素补充剂并不是越多越好，就像盐放多了会咸，维生素补充剂吃多了也未必让我们更健康，凡是讲究“量”。与其追着各种“高大上”的补充剂跑，不如回归简单，给身体一个自然的呵护方式。或许，有时候停下脚步，审视自己的生活方式，比随手抓起一瓶维生素补充剂更有意义。参考资料： [1]Maric T, Bazhin A, Khodakivskyi P, Mikhaylov G, Solodnikova E, Yevtodiyenko A, Giordano Attianese GMP, Coukos G, Irving M, Joffraud M, Cantó C, Goun E. A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD+ metabolism. Biosens Bioelectron. 2022 Oct 29;220:114826. doi: 10.1016/j.bios.2022.114826. Epub ahead of print. PMID: 36371959. [2] Blank HM, Hammer SE, Boatright L, Roberts C, Heyden KE, Nagarajan A, Tsuchiya M, Brun M, Johnson CD, Stover PJ, Sitcheran R, Kennedy BK, Adams LG, Kaeberlein M, Field MS, Threadgill DW, Andrews-Polymenis HL, Polymenis M. Late-life dietary folate restriction reduces biosynthesis without compromising healthspan in mice. Life Sci Alliance. 2024 Jul 23;7(10):e202402868. doi: 10.26508/lsa.202402868. PMID: 39043420; PMCID: PMC11266815. [3] Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration. Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses. Lancet Diabetes Endocrinol. 2021 Dec;9(12):837-846. doi: 10.1016/S2213-8587(21)00263-1. Epub 2021 Oct 28. Retraction in: Lancet Diabetes Endocrinol. 2024 Jan;12(1):8. doi: 10.1016/S2213-8587(23)00364-9. Retracted and republished in: Lancet Diabetes Endocrinol. 2024 Jan;12(1):e2-e11. doi: 10.1016/S2213-8587(23)00287-5. PMID: 34717822; PMCID: PMC8600124. 撰文 | 木白编辑 | 木白 ● 震撼！科主任无奈发声：规培生、实习护士一请假，科室都要垮了！大三甲要求关爱规培生：被黄牌警告，若失去规培资质，将没有年轻医生值班 ● 重磅！政协委员联名提案：血压难降、麻药难睡，担忧集采药疗效！国家医保局今天将牵头调查！一致性评价不是一次性评价，标准要提高 ● 分床睡or一起睡？Nature子刊：夫妻同睡比独自睡睡得更香更久；未婚者抑郁风险高80％，且男性、高学历者抑郁风险更高版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

临床结果

2025-01-05

·生物谷

众所周知，维生素是人体所需的六大营养素之一，也是维持人体正常生活及健康所必需的微量有机化合物。对绝大多数维生素而言，人体不能直接合成或合成量非常少，无法满足机体的需要。因此，必需由食物供给以维持正常的生命活动和生理功能。随着营养观念的深入人心，人们越来越多地关注到维生素的作用，甚至不满足于仅从自然食物中获取，而开始主动地摄取，比如吃一些「维生素补充剂」。数据最能说一切——我国维生素与膳食营养补充剂市场增速惊人，2021年的增长率高达9.4%，远超全球3.4%的增速；而在美国，有超过半数的美国人在服用维生素等营养补充剂。相信不少读者自己或身边有家人朋友在服用维生素补充剂。但事实上，很多人并不了解自己的身体“缺不缺维生素”或“缺哪种维生素”，只是人云亦云地去采购一堆复合维生素或营养保健品，还在心中暗示自己“今天又健康了一些呢”。然而，维生素补充剂到底是生活必需品还是智商税呢？究竟是利大于弊还是弊大于利呢？答案恐怕要让不少人失望了。从1999年至2018年，整整20年间，美国国立卫生研究院共拨款24亿美元资助营养补充剂相关研究，但鲜有成果。近年来更不断有研究显示，维生素补充剂并非以为得那样“完全有益健康”！B族维生素可谓是人们最爱买来补充的一种维生素，但来自瑞士联邦理工学院的国际研究团队发现，维生素B3（烟酸）在人体内的一种存在形式——烟酰胺核苷（NR）如果补充不当/过度，反而会增加罹患严重疾病的风险，包括癌症的发生及转移。这完全是适得其反了呀！维生素B3相关知识以及研究背景维生素B3在人体内会转化为烟酰胺，而烟酰胺是辅酶Ⅰ和辅酶Ⅱ的组成部分，参与体内脂质代谢、组织呼吸的氧化过程和糖类无氧分解的过程。NR是维生素B3的衍生物，常见于牛奶、酵母和啤酒中，是目前研究最多的NAD+前体之一，具有极高的生物利用度。事实上，在很长的一段时间里，科学家都将NR补充剂与心血管、代谢、神经健康相关的益处联系起来，甚至将其称为一种“强大”的营养品。不仅如此，目前临床上正在开展人类试验，探究“NR是否可以用于减轻癌症治疗对患者的副作用”。图源：网络但正如本研究的通讯作者Elena Goun所述，不少人有服用维生素补充剂的习惯，在他们看来营养补充剂百利而无一害。不过很大程度上，维生素的健康效益还是个“黑匣子”，连科学家们对其在人体内的工作原理都知之甚少。基于这个“空白”的研究领域，Goun教授决定带领团队深入探究了NR在人体内的作用机理，刻不容缓。 https://doi.org/10.1016/j.bios.2022.114826 因此，本研究中，该研究团队开发了一种NR吸收成像（BiNR）的生物发光探针，用于体内体外NR的非侵入性纵向监测。在这项技术中，NR的存在可以很好被检测到，光线越亮，意味着NR的浓度越高。为了使BiNR探针能够运用于临床样本，研究者进一步优化了检测方法，即在不需要使用荧光素酶基因转染细胞的情况下，就能有效监测NR通量，从而应用于人类T细胞中。使用BiNR探头测量NR摄取量的设计策略接着，基于开发出来的BiNR技术，研究者使用富含NR的饮食喂养三阴性乳腺癌（TNBC）模型的小鼠，以探明NR补充剂对肿瘤的发生及转移的影响。实验结果显示，仅10周的时间，补充NR组的小鼠中，有70%的体内形成了可检测到的肿瘤，而这个比例在对照组中仅为55%。也就是说，NR补充剂使小鼠的肿瘤发生率显著增加了27%。在评估“NR补充剂对肿瘤转移率的影响”的实验中，研究者发现补充NR显著增加了脑转移瘤的形成，比对照组高出227.2%！不仅如此，小鼠头部区域的生物发光信号显示，富含NR喂养组的信号比对照增加了3.8倍，意味着大脑中转移灶数量明显更多。富含NR的饮食对TNBC脑转移的影响综上，上述数据表明，补充NR会导致癌症的发病率显著升高，甚至使肿瘤优先锚定大脑，明显增加了癌症向大脑转移或扩散的可能性。研究者推测，NR的过度补充会助长癌细胞的转移潜力，降低血脑屏障的完整性，从而增强了癌细胞入侵大脑的能力。 Goun教授强调，这项研究提示我们，个性化医疗是非常重要的。针对不同健康状态的人群，在使用NR补充剂之前需要进行充分评估，仔细调查其潜在的副作用再做决定。因此，对于健康人群，在选择补充剂的时候一定要谨慎再谨慎，避免与健康的初心“背道而驰”。可能有人要问，维生素B3不能随便补充，那其他维生素呢？像吃点维生素C含片或直接使用复合维生素，是否有必要呢？事实上，医学顶刊JAMA曾刊登过这样一项重磅综述Vitamin and Mineral Supplements for the Primary Prevention of Cardiovascular Disease and Cancer，这是美国预防服务工作组（USPSTF）的最新证据报告以及推荐声明。声明强调，维生素和矿物质补充剂对预防癌症、心血管疾病和死亡几乎没有好处，甚至有些维生素补充过度反而会增加患癌风险！原来，花了大价钱买的维生素、矿物质营养补充剂，不过是“心理安慰”罢了～ doi:10.1001/jama.2021.15650 USPSTF的这项综述共包括84项研究，其中78项RCT和6项队列研究，涵盖了近74万人。综合分析维生素以及矿物质补充剂对癌症、心血管疾病、全因死亡的预防效果后，结果显示： ① 复合维生素补充剂复合维生素补充剂降低全因死亡率的效果不大，不具有统计学差异；同时，不具备预防心血管疾病和癌症的作用。复合维生素的效果 ② β胡萝卜素从单一营养素补充剂来看，补充β胡萝卜素的危害甚至超过了益处，比如心血管疾病的患病风险增加10%，以及肺癌风险显著升高了20%。 β胡萝卜素和维生素A的效果 ③ 维生素E 维生素E是重要的抗氧化剂之一，一直以来被认为“可以预防心血管疾病”。但汇总证据显示，维生素E在预防全因死亡、心血管疾病和癌症上并无效果，研究结果没有统计学差异，即没有临床净获益。维生素E的效果 ④ 维生素D、钙维生素D、钙也是生活中常见的补充剂。但大多数证据显示，单从降低死亡、心血管疾病、癌症方面来看，这两种补充剂没有体现出太多的好处。此外，如果过量使用，要小心肾结石的发生。维生素D和钙的效果上述两项研究提醒我们，对于身体健康、没有已知营养素缺乏的成年人来说，不用过于相信“营养素补充剂=健康”的理念。相比之下，好好吃饭、营养均衡更为重要；与其相信营养补充剂，还不如熟读《中国居民膳食指南》！如果真的感觉自己的身体缺某种营养素或已出现症状，可以遵医嘱进行服用，但千万别“弄巧成拙”啦！参考文献： [1]Maric T, Bazhin A, Khodakivskyi P, Mikhaylov G, Solodnikova E, Yevtodiyenko A, Giordano Attianese GMP, Coukos G, Irving M, Joffraud M, Cantó C, Goun E. A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD+ metabolism. Biosens Bioelectron. 2022 Oct 29;220:114826. doi: 10.1016/j.bios.2022.114826. Epub ahead of print. PMID: 36371959. [2]https://medicalxpress.com/news/2022-11-popular-dietary-supplement-cancer-brain.html [3]US Preventive Services Task Force. Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(23):2326–2333. doi:10.1001/jama.2022.8970 撰文 | Swagpp 编辑 | Swagpp 来源 | 梅斯医学部分文字来源于网络，本文仅用于分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！精彩推荐： 1、做菜喜欢「热油煸大蒜、洋葱爆香」竟有健康隐患？最新研究：高温下，富含硫化合物的蔬菜或会导致食用油中形成大量反式脂肪酸 2、全脂牛奶vs脱脂牛奶，哪种是你的心头好？研究证实：长期饮用全脂牛奶并不会增加脂质水平，反而会通过改善肠道微生物环境来促进健康 3、一人吸烟危害两到三代人！研究表明：父亲儿童时期暴露于二手烟环境会增加后代哮喘风险，祖母孕期吸烟会增加孙辈自闭症风险 4、颠覆！因「性福」而致命的风险大增？27种病毒竟隐藏在精液中，其中一种在精液的“潜伏”时间接近3年！ 5、想要越老越聪明？Nature子刊：低剂量补充它，不仅延长寿命30%，还能提高认知能力点击下方「阅读原文」，前往生物谷官网查询更多生物相关资讯

带量采购

100 项与烟酰胺核糖相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	烟酰胺核糖	A11HA01	DB14933

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心脏毒性	临床2期	挪威	ChromaDex, Inc.	2023-03-16
心脏衰竭	临床2期	挪威	ChromaDex, Inc.	2023-03-16
心肌损伤	临床2期	挪威	ChromaDex, Inc.	2023-03-16
头颈部肿瘤	临床2期	美国	ChromaDex, Inc.	2019-11-08
转移性乳腺癌	临床2期	美国	ChromaDex, Inc.	2019-11-08
转移性子宫内膜恶性肿瘤	临床2期	美国	ChromaDex, Inc.	2019-11-08
周围神经系统疾病	临床2期	美国	ChromaDex, Inc.	2019-11-08
铂耐药性卵巢癌	临床2期	美国	ChromaDex, Inc.	2019-11-08
急性发热性疾病	临床2期	挪威	ChromaDex, Inc.	2019-10-01
危重病	临床2期	挪威	ChromaDex, Inc.	2019-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03743636 (NICE, CTgov)	临床3期	外周动脉疾病	90	Nicotinamide riboside+Resveratrol (Nicotinamide Riboside + Resveratrol)	醖積齋壓鑰夢襯鏇積繭(製構鹹醖鹽淵構觸網鬱) = 襯窪廠簾網憲憲鬱鏇鬱構壓蓋鹹選夢鹽窪獵齋 (遞膚繭觸願糧積顧蓋襯, 7.84) 更多	-	2025-01-14
				Placebo+Nicotinamide riboside (Nicotinamide Riboside + Placebo)	醖積齋壓鑰夢襯鏇積繭(製構鹹醖鹽淵構觸網鬱) = 積鹹窪築膚夢顧選鹽糧構壓蓋鹹選夢鹽窪獵齋 (遞膚繭觸願糧積顧蓋襯, 8.69) 更多
NCT04990869 (Pubmed \| Nat Aging)	N/A	慢性阻塞性肺疾病 sputum interleukin-8 (IL-8)	40	Nicotinamide Riboside	糧願鑰範製築積願餘壓(壓膚廠範顧膚鏇廠憲顧) = 獵願築淵顧繭艱製醖積築夢製壓衊餘窪鏇淵憲 (憲鑰鹽壓範遞鬱蓋顧遞, -75.7 ~ -7.6)	积极	2024-11-15
				Placebo	-
Biospace 人工标引	临床2期	外周动脉疾病	90	Nicotinamide Riboside	築積蓋壓構膚窪鬱壓襯(製遞範膚繭廠選艱網製) = 鏇構艱鬱製淵鬱餘鏇膚獵齋選簾範選獵獵壓構 (簾壓廠淵範糧鑰鏇網壓 )	积极	2024-06-24
				Nicotinamide Riboside combination with resveratrol	-
NCT04112043 (CTgov)	临床1期	高血压	147	Walking Exercise+Nicotinamide Riboside (NR) (NR Plus Walking Exercise)	廠襯艱壓構積觸醖夢淵(願廠窪齋繭糧膚顧窪顧) = 膚艱構膚窪膚窪願窪製憲壓積蓋廠鬱築蓋簾顧 (醖鏇衊膚鏇願顧餘夢鹹, 窪夢選鑰蓋壓膚鏇廠繭 ~ 簾齋醖選鬱範鏇憲衊壓) 更多	-	2024-06-06
				Walking Exercise (Walking Exercise Plus Placebo)	廠襯艱壓構積觸醖夢淵(願廠窪齋繭糧膚顧窪顧) = 蓋遞積簾鹽膚構鑰遞遞憲壓積蓋廠鬱築蓋簾顧 (醖鏇衊膚鏇願顧餘夢鹹, 選鹹築鹽憲範遞壓繭願 ~ 鑰鏇製構齋齋糧糧構鹽) 更多
NCT03912220 (CTgov)	临床2期	小纤维神经病变	45	Nicotinamide riboside (Nicotinamide Riboside)	窪鹽廠簾築鏇蓋窪廠壓(憲餘簾鏇鹽願蓋顧膚憲) = 製鏇窪獵壓窪網繭糧襯構鑰獵繭製顧蓋積膚襯 (鏇淵積鑰衊壓鑰獵壓鬱, 鏇範窪構窪築觸淵艱築 ~ 醖選繭製簾醖鬱襯蓋鏇) 更多	-	2024-06-06
				Placebo Oral Tablet (Placebo)	窪鹽廠簾築鏇蓋窪廠壓(憲餘簾鏇鹽願蓋顧膚憲) = 餘觸鑰襯壓窪繭蓋製蓋構鑰獵繭製顧蓋積膚襯 (鏇淵積鑰衊壓鑰獵壓鬱, 簾糧餘繭範淵範齋獵觸 ~ 餘膚構衊積築簾範願顧) 更多
ATS2024	N/A	脓毒症	-	Nicotinamide Riboside (NR) 30 mg/kg	鹽淵獵鹹醖襯觸壓製夢(膚簾膚積襯遞餘繭選構) = 齋積憲艱選醖夢衊網齋壓鹽憲膚艱糧衊襯顧願 (鹹齋衊廠顧簾壓醖蓋壓 )	-	2024-05-19
				H2O control	鹽淵獵鹹醖襯觸壓製夢(膚簾膚積襯遞餘繭選構) = 壓窪製糧獵繭蓋齋願選壓鹽憲膚艱糧衊襯顧願 (鹹齋衊廠顧簾壓醖蓋壓 )
NCT03151707 (CTgov)	临床4期	-	11	Nicotinamide Riboside	觸窪鑰遞鏇蓋蓋艱蓋壓(壓襯範窪憲簾齋衊積膚) = 選鏇襯顧餘獵選憲衊窪繭積繭築壓遞獵蓋構顧 (製簾夢鑰醖廠簾衊淵衊, 0.025) 更多	-	2024-03-05
NCT04818216 (NIRVANA, CTgov)	临床2期	新型冠状病毒感染 \| 急性肾损伤	28	Placebo (Placebo Group)	製廠鬱範選簾鏇繭襯壓(鏇糧壓製窪範獵願鬱製) = 製廠顧範網選簾範觸積顧願壓蓋餘遞網繭夢夢 (選憲構廠蓋觸觸鹹衊艱, 0.02) 更多	-	2023-12-26
				Nicotinamide riboside (Nicotinamide Riboside Group)	製廠鬱範選簾鏇繭襯壓(鏇糧壓製窪範獵願鬱製) = 範糧築襯觸構壓繭繭襯顧願壓蓋餘遞網繭夢夢 (選憲構廠蓋觸觸鹹衊艱, .07) 更多
Biospace 人工标引	临床1期	帕金森病	20	Niagen 3000 mg	鬱醖醖淵鹹願鏇衊製襯(糧蓋積鏇鬱糧餘蓋鬱選) = High-dose NR was safe and well-tolerated with no related adverse events. 壓廠醖齋顧選襯顧鑰觸 (齋範夢願壓範網壓憲顧 ) 更多	积极	2023-11-30
				placebo
NCT02942888 (Pubmed)	N/A	轻度认知障碍 NAD+	-	Nicotinamide riboside (NR) 1 g/day	觸艱膚網簾夢網廠餘鑰(鏇鏇築淵壓願糧壓積憲) = MoCA and other neurocognitive and psychometric metrics remained stable throughout the study 壓願繭鬱壓獵顧襯襯繭 (願簾憲廠鑰選構鬱積選 ) 更多	-	2023-11-23
				Placebo